User profiles for C. Lieu

Christopher Lieu

UNIVERSITY OF COLORADO
Verified email at cuanschutz.edu
Cited by 7882

Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists …

…, WK Funkhouser, SE Kopetz, C Lieu… - American journal of …, 2017 - academic.oup.com
… There is insufficient evidence to recommend BRAF c.1799 p.V600 mutational status as a
predictive molecular biomarker for response to anti-EGFR inhibitors. No recommendation …

Characteristics of early-onset vs late-onset colorectal cancer: a review

…, JH Lefèvre, A Lepisto, C Lieu, L Loi, C Lynch… - JAMA …, 2021 - jamanetwork.com
Importance The incidence of early-onset colorectal cancer (younger than 50 years) is rising
globally, the reasons for which are unclear. It appears to represent a unique disease process …

[HTML][HTML] ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper

…, SA Jacobs, HF Kennecke, JJ Lee, CH Lieu… - Nature reviews Clinical …, 2020 - nature.com
… at progressively increasing speeds (800–1,600 g) at 4C or through filtration followed by
immediate deep freezing (typically at –80C) 20,21,22 . Immune cells obtained from the buffy coat …

Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology

…, A Kardan, SA Khan, BW Kuvshinoff, C Lieu… - Journal of the National …, 2021 - jnccn.org
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine
and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients …

[HTML][HTML] Treatment of metastatic colorectal cancer: ASCO guideline

…, TS Hong, I Jaiyesimi, K Klute, C Lieu… - Journal of clinical …, 2023 - ncbi.nlm.nih.gov
… OS (coprimary outcome) at data cutoff (median 32.4 months) HR, 0.74 (95% CI 0.53 to
1.03) 34 (296 patients in one study) 448 deaths per 1,000 356 deaths per 1,000 Low a,b,c …

[HTML][HTML] Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated …

…, MJ Overman, V Valero, S Wen, C Lieu… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
… (C) Progression-free survival for patients with interleukin-8 levels above and below the … a
lesser extent with stem cell factor (SCF)/c-kit ligand, with average levels returning to normal at …

Neuroendocrine tumors, version 1.2015

…, F Kandeel, PL Kunz, BW Kuvshinoff, C Lieu… - Journal of the National …, 2015 - jnccn.org
Neuroendocrine tumors (NETs) comprise a broad family of tumors that may or may not be
associated with symptoms attributable to hormonal hypersecretion. The NCCN Clinical …

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

B Tran, S Kopetz, J Tie, P Gibbs, ZQ Jiang, CH Lieu… - Cancer, 2011 - Wiley Online Library
BACKGROUND: It is hypothesized that BRAF mutant cancers represent a discrete subset of
metastatic colorectal cancer (CRC) defined by poorer survival. This study investigates …

Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion

…, J Perlmutter, SW Gray, J Hwang, C Lieu… - Journal of Clinical …, 2022 - ingentaconnect.com
PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …

NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018

…, WZ Kidwai, PL Kunz, BW Kuvshinoff, C Lieu… - Journal of the National …, 2018 - jnccn.org
The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations
for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland …